Ocrevus (ocrelizumab) is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug candidate.[1] Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds. Ocrevus (ocrelizumab) is a prescription medicine used to treat adults with relapsing or primary progressive forms of multiple sclerosis. On March 28, the U.S. Food and Drug Administration approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS). This is the first drug approved by the FDA for PPMS. Ocrevus (ocrelizumab) is an intravenous infusion given by a health care professional.
